|Description||LDN-214117 is a selective and potent ALK2 inhibitor. LDN-214117 inhibited ALK2 most, with a biochemical IC50 of 24 nM. There are currently no effective therapies for fibrodysplasia ossificans progressiva (FOP), a debilitating and progressive heterotopic ossification disease caused by activating mutations of ACVR1 encoding the BMP type I receptor kinase ALK2. LDN-214117 shows a high degree of selectivity for ALK2 and low cytotoxicity that could provide a template for preclinical development.|
|Synonyms||LDN-214117; LDN 214117; LDN214117|
LDN193189 HCl is the hydrochloride salt of LDN193189, which is a selective BMP signaling inhibitor, and inhibits the transcriptional activity of the BMP type I ...
AP26113 is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with pote...
Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK. Crizotinib inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM). Crizotinib is use...
R-268712 is a potent and selective inhibitor of TGF-β type I receptor/ALK5 with an IC50 of 2.5 nM, an approximately 5000-fold more selectivity for ALK5 than p38...
DMH-1 is a second-generation small molecule BMP inhibitor based on dorsomorphin. DMH-1 effectively inhibits the bone morphogenic protein (BMP) ALK2 receptor (IC...
CEP-14083 is a ALK inhibitor. It has a potent activity against ALK in enzymatic assays (IC50 = 11 nmol/L). CEP-14083 can also inhibit the insulin receptor at a ...
IN-1130 is a selective ALK5 inhibitor with >100 fold selectivity over p38α and a panel of 26 other serine/threonine and tyrosine kinases. It also inhibit phosph...
ALK inhibitor 1
ALK inhibitor 1 is a novel and selective inhibitor for the ALK kinase.
CH5424802 Hcl (AF 802 Hcl; Alectinib Hcl) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.
Brigatinib, is an orally active, also known as AP-26113, potent and selective Dual ALK/EGFR inhibitor. AP26113 binds to and inhibits ALK kinase(ALK belongs to t...
K02288 is a highly selective 2-aminopyridinebased inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current le...
TPX-0005 is an orally available and potent ATP-competitive inhibitor of ALK/ROS1/TRK (IC50= 5.3 nM for SRC, IC50= 1.01 nM, 1.26 nM and 1.08 nM for mutant ALKs i...
LDN193189 is a selective and potent ALK inhibitor with potential anticancer activity.
HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.
GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively. GSK1838705A blocks ...
BAY-754 is an ALK-1 inhibitor used as an anti-angiogenesis agent. It inhibited the eye vascular leakage in dose manner in mouse model.
SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptor ALK5 and as well as being a selective inhibitor of ALK4 but with less pote...
CEP-14513 is a ALK inhibitor. It shows ALK inhibitory activity in both in vitro enzymatic assay (IC50 = 5 nM) and cell-based assays of ALK tyrosine phosphorylat...
AZD-3463 is a potent ALK/IGF1R inhibitor with potential anticancer activity.
CEP-37440 is an orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with po...